Academic Medicine Delivers Hope To Sufferers (2) can tell companies and bloggers the best place to have their websites hosted. It isn’t gambling, or at least no more so than betting a dollar on the toss of a coin, because the answer will be right sometime. Cancer sufferers have known for centuries that, in the case of their problem, too, there was an outcome and it was a fairly certain one at that. At long last, and thanks to the work being done in academic medicine, things are changing.

Metastatic melanoma is a form of skin cancer in which the melanoma has spread (metastasized) to other parts of the body – most often, bones, lungs, liver, or even the brain. It happens because the melanoma was not identified early enough, and this does not have to be due to negligence – it is sometimes true that it is only after the cancer has spread that any symptoms appear. What has to happen then is that, while the physician is presented with what may look like – for example – liver cancer, the original melanoma has to be identified if there is to be any hope of treatment.

It follows that the prognosis is not always been optimistic, and the emergence of the drug Opdivo is therefore extremely welcome.

Another cancer for which the future of sufferers begins to look better is non-small cell lung cancer, for which the immunotherapy drug Keytruda is producing remarkable results with a 50% reduction when compared to chemotherapy, with the likelihood that the patient’s condition will worsen or that the patient will die. Where chemotherapy produced a response rate of 28%, the response rate with Keytruda is 45%.

Finally, the introduction of the drug Cabometyx has been shown to be extremely powerful in treating renal cell carcinoma (cancer of the kidney). Survival rates have increased dramatically, and the improvement in patients’ quality of life is remarkable.